Integrated genomic meta-analysis identifies cell-type-specific signatures and targets in early Alzheimer's disease
TL;DR
A systematic analysis of cell-type-specific changes in early Alzheimer's disease to prioritise pathways for investigation and therapeutics for repurposing is presented.
Abstract
Cellular mechanisms in early Alzheimer's disease (AD) remain poorly understood despite generation of extensive observational multiomic data. Weighted integration across diverse datasets can prioritise convergent mechanisms and targets. We conducted a systematic review to identify datasets profiling cell-type-specific changes in early AD. We integrated multiomic findings using Meta-Analysis by Information Content (MAIC), a computational method which combines genomic data from diverse experimental sources. Electron transport chain dysfunction in mitochondria emerged as a shared pathway in neurons, microglia, and astrocytes, and Wnt signalling was a prominent astrocyte-specific signature. Pathological neuro-glial signalling mechanisms included APP-CD74, APOE-SORL1, and WNT-FZD/LRP6. Integration with pharmacological data identified therapeutics already under investigation in AD, such as guanfacine, and candidates not previously prioritised, such as eltrombopag and encorafenib. We present a systematic analysis of cell-type-specific changes in early AD to prioritise pathways for investigation and therapeutics for repurposing.